COMPARATIVE EFFECTS OF PARATHYROID HORMONE AND ALENDRONATE ON BONE TURNOVER MARKERS, BONE MINERAL DENSITY, AND BONE MATRIX MATURATION IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
Main Article Content
Keywords
Osteoporosis and PTH and Alendronate and Bone turnover markers and Bone mineral density and Postmenopausal women.
Abstract
The osteoporosis condition represents low bone density and a high probability of fracture, and it is one of the major disorders affecting postmenopausal women. This study compared the effects of parathyroid hormone (PTH) [PTH ] and alendronate on bone turnover and bone mineral density (BMD) in osteoporotic postmenopausal women. The study consisted of two groups: one that took PTH and the other that took alendronate. PINP, CTX, and a urinary 2:1 alpha/beta CTX percentage were the major biochemical markers of bone turnover that changed. Dual-energy X-ray absorption (DXA) was used to assess secondary outcomes such as changes in BMD. Comparatively to alendronate, which is largely inhibiting bone resorption, PTH increased bone resorption markers, specifically urinary 2 2 CTX/Cr. By measuring serum PINP levels, both treatments significantly reduced bone formation. Although the alpha alpha/beta beta CTX ratio didn't differ significantly between the groups, there were significant differences between the two. PTH and alendronate act oppositely on bone turnover, accelerating bone formation and suppressing resorption in most cases, while alendronate suppresses resorption of the bone in most cases. In order to develop a better understanding of the long-term effects of these treatments on bone strength, fracture risk, and collagen maturation in a matrix, more research is needed.
References
2. Fitzpatrick, L. A., Dabrowski, C. E., Cicconetti, G., Gordon, D. N., Papapoulos, S., Bone, H. G., & Bilezikian, J. P. (2011). The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density. The Journal of Clinical Endocrinology & Metabolism, 96(8), 2441–2449. https://doi.org/10.1210/jc.2010-2855
3. Garnero, P., Vergnaud, P., & Hoyle, N. (2008). Evaluation of a Fully Automated Serum Assay for Total N-Terminal Propeptide of Type I Collagen in Postmenopausal Osteoporosis. Clinical Chemistry, 54(1), 188–196. https://doi.org/10.1373/clinchem.2007.094953
4. Girotra, M., Rubin, M. R., & Bilezikian, J. P. (2006). The use of parathyroid hormone in the treatment of osteoporosis. Reviews in Endocrine and Metabolic Disorders, 7(1–2), 113–121. https://doi.org/10.1007/s11154-006-9007-z
5. Mcclung, M. R., San Martin, J., Miller, P. D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D. W., Dalsky, G. P., & Eriksen, E. F. (2005). Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass. Archives of Internal Medicine, 165(15), 1762. https://doi.org/10.1001/archinte.165.15.1762
6. Olmos, J. M., Hernández, J. L., Llorca, J., Nan, D., Valero, C., & González-Macías, J. (2012). Effects of 25-Hydroxyvitamin D3 Therapy on Bone Turnover Markers and PTH Levels in Postmenopausal Osteoporotic Women Treated with Alendronate. The Journal of Clinical Endocrinology & Metabolism, 97(12), 4491–4497. https://doi.org/10.1210/jc.2012-2999
7. Reid, D. M., Hosking, D., Kendler, D., Brandi, M. L., Wark, J. D., Marques-Neto, J. F., Weryha, G., Verbruggen, N., Hustad, C. M., Mahlis, E. M., & Melton, M. E. (2008). A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. International Journal of Clinical Practice, 62(4), 575–584. https://doi.org/10.1111/j.1742-1241.2008.01704.x
8. Rittmaster, R. S., Bolognese, M., Ettinger, M. P., Hanley, D. A., Hodsman, A. B., Kendler, D. L., & Rosen, C. J. (2000). Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. The Journal of Clinical Endocrinology & Metabolism, 85(6), 2129–2134. https://doi.org/10.1210/jcem.85.6.6614
9. Seikaly, M. G., Kopanati, S., Salhab, N., Waber, P., Patterson, D., Browne, R., & Herring, J. A. (2005). Impact of Alendronate on Quality of Life in Children With Osteogenesis Imperfecta. Journal of Pediatric Orthopaedics, 25(6), 786–791. https://doi.org/10.1097/01.bpo.0000176162.78980.ed
10. Sornay‐Rendu, E., Boutroy, S., Duboeuf, F., & Chapurlat, R. D. (2017). Bone Microarchitecture Assessed by HR-pQCT as Predictor of Fracture Risk in Postmenopausal Women: The OFELY Study. Journal of Bone and Mineral Research, 32(6), 1243–1251. https://doi.org/10.1002/jbmr.3105
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Rajinikanth.S
Assistant Professor, Department of Orthopedic, Sri Lakshmi Narayana Institute of Medical Science, Pondicherry, India.
